Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Earlier this month, I sat down for a Pulse Check with Dr. Patrick O’Shaughnessy, president and CEO of Catholic Health: a six ...

Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...

Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...

In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now available for patients in India. With Cipla handling nationwide ...

The Limb Salvage Clinic in San Antonio integrates cardiovascular and podiatric teams to help patients find solutions.

Knownwell picked up $25 million in fresh funding, riding the wave of investment in obesity care. | LAS VEGAS—Over the last 18 ...

Get the latest healthcare stock updates, key pharma deals, and major legal developments impacting the S&P 500.

Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come ...